Kineticos Life Sciences Fund Announces Successful Final Close of approximately $60 Million for Kineticos Disruptor Fund II (KDF II)
RALEIGH, N.C. | November 17, 2023 — Kineticos Life Sciences is pleased to announce the successful final close of
Kineticos Disruptor Fund II (KDF II or the Fund) with $57.3 million in committed capital. KDF II, a growth equity and venture fund, intends to invest in revolutionary life sciences companies by focusing on addressing significant, unmet medical needs in the fields of oncology, neurosciences, and rare diseases. The Fund has strategically invested in early-stage life science companies that leverage disruptive technologies such as cell and gene therapy, gene editing, and mRNA/RNAi, which are poised to reshape the landscape of medicine.
KDF II has a diverse group of investors, including life science pioneers, family offices, and high-net-worth individuals who share Kineticos’s vision of A World Without Cancer, Rare and Neurodegenerative Diseases, and Antimicrobial Resistance™ . The successful close of KDF II reflects the strong confidence in Kineticos; history of identifying and supporting innovative companies that are at the forefront of transforming healthcare.
“I am proud of the Kineticos team for reaching this significant milestone with the final close of KDF II” said Shailesh Maingi, Founder of Kineticos. “Our commitment to identifying and supporting groundbreaking companies with disruptive technologies in life sciences aligns with the evolving needs of patients and healthcare professionals. KDF II will play a pivotal role in advancing these technologies, which have the potential to fundamentally change the way we practice medicine.”
KDF II will primarily target early-stage life science companies in their Seed to Series B rounds of funding. The focus will be on contract services and manufacturing, equipment and biotechs with a specific focus on companies with differentiated platform technologies in the fields of cell and gene therapy, gene editing, and mRNA/RNAi. These technologies have already demonstrated their potential to revolutionize disease treatment and management, offering innovative solutions for patients who are facing significant, unmet medical needs.
Kineticos has earned a reputation for its deep expertise in the life sciences sector and its ability to provide strategic guidance and resources to portfolio companies. With KDF II, Kineticos will continue to play a critical role in nurturing and accelerating the growth of companies poised to make a profound impact on healthcare.
Kineticos Life Sciences is a growth and venture investor focused on companies striving to disrupt how drugs are developed, diseases are diagnosed, and patients are treated. Kineticos invests in companies focused on significant, unmet medical needs in oncology, neurosciences, rare diseases and antimicrobial resistance across contract services, manufacturing, equipment, and therapeutic companies. In addition to targeting these disease states with patients in need, we look for life science companies utilizing disruptive technologies such as cell and gene therapy, gene editing, and mRNA/RNAi, all technologies dramatically changing how medicine is practiced.